Clinical trials: Head and Neck Squamous Cell Carcinomas
Human Papilloma Virus, Oropharyngeal Squamous Cell Carcinoma
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
In general, patients with Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma (HPVOPC) are curable, young and will live for prolonged periods.
- Trial name
- NCT02072148
- Testing
- PET/CT, Radiotherapy, Concurrent Chemoradiation
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Oropharyngeal Squamous Cell Carcinoma
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging
Known risk factors inducing squamous cell carcinomas of the head and neck are tabacco and alcohol intake. However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing.
- Trial name
- PIVOT (NCT04222543)
- Testing
- RGD PET/CT
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head…
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06912087
- Testing
- Zanzalintinib, Cetuximab, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Head and Neck Neoplasms
Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Concomitant radio-chemotherapy has become a standard therapy for advanced squamous cell carcinomas of head and neck. Local side effects caused by chemotherapy, like mucositis, increase in combination with radiotherapy.
- Trial name
- NCT02015650
- Testing
- Cetuximab, Mitomycin-C/ 5-Fluorouracil
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University Innsbruck
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Head-and-neck Squamous Cell Carcinoma
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT05423197
- Testing
- 89Zr-panitumumab IV, Panitumumab
- Where
- United States
- Sponsor
- Andrei Iagaru
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally…
- Trial name
- NCT04080804
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Dan Zandberg
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
- Trial name
- NCT00021424
- Testing
- recombinant fowlpox-TRICOM vaccine
- Where
- United States
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
HNSCC
Bacterial Decolonization to Prevent Severe Radiation Dermatitis in Head and Neck Squamous Cell Carcinoma
Radiation dermatitis is a common and potentially treatment-limiting toxicity of radiotherapy for head and neck cancers. Colonization with Staphylococcus aureus has been identified as a risk factor for clinically significant…
- Trial name
- DECORL (NCT07888907)
- Testing
- Bacterial decolonization, Standard Hygiene Measures
- Where
- 7 sites in France
- Volunteers
- 144 people
- Sponsor
- Institut Cancerologie de l'Ouest
Squamous Cell Carcinoma of the Head and Neck
Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection
Early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract.
- Trial name
- TEPVAD (NCT02510872)
- Testing
- 18F-FDG PET combined with CT with iodinated contrast injection, 18F-FDG PET combined with CT without injection
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Caen
Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma
Validity of Viome's Oral/throat Cancer Test
A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S.
- Conditions
- Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
- Trial name
- NCT06174428
- Testing
- Oral/Throat cancer test
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Viome
HNSCC
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition (phosphatidylinositol-3-kinase/ mammalian target of…
- Trial name
- HNSCC (NCT03740100)
- Testing
- Bimiralisib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
The purpose of this trial is to compare two different treatments for fit patients with head and neck cancer: All patients are given induction-chemotherapy (docetaxel, cisplatin, 5-FU).
- Trial name
- Condor (NCT00774319)
- Testing
- conventional radiotherapy with 'high' dose cisplatin, accelerated radiotherapy with 'low' dose cisplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Head and Neck Neoplasms, Carcinoma, Squamous
ctDNA and MRI Parameters in Head and Neck Cancer
Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study.
- Trial name
- NCT06215612
- Testing
- Blood draw, MRI
- Volunteers
- 50 people
- Sponsor
- Franziska Eckert
Esophageal Cancer, Squamous Cell Carcinoma
Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer
The purpose of this study is to clarify efficacy and toxicity of daily low-dose Nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT00197444
- Testing
- CDGP/5-FU combined with radiation, Radiotherapy
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Hamamatsu University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.